Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
P-779 GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications - A nationwide cohort study
Since ceruloplasmin binds 85-95% of circulating copper and facilitates its safe transport, reduced synthesis means a higher fraction of "free" (non-ceruloplasmin-bound) copper in circulation
In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation
The principal advantages of microparticulate delivery systems include controlled and sustained drug release, enhanced bioavailability, improved physicochemical stability, and site-specific targeting, all of which contribute to optimized therapeutic outcomes and increased patient adherence [35]
US$ 27.92
US$ 25.91
US$ 27.83
US$ 28.59
US$ 25.34
US$ 27.58
US$ 24.43
US$ 22.64
US$ 20.30
US$ 27.88
